Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. - Test2 - elhamkhani - TriplyDB

Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

http://www.wikidata.org/entity/Q41861051

about

Chemical Variations on the p53 Reactivation Theme Focusing on shared subpockets - new developments in fragment-based drug discovery Exhaustive Fluorine Scanning toward Potent p53-Mdm2 Antagonists Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction Two strategies for the development of mitochondrion-targeted small molecule radiation damage mitigators Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists A chemoselective Ugi-type reaction in water using TMSCN as a functional isonitrile equivalent: generation of heteroaromatic molecular diversity.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism In silico identification of an interferon inhibitor.Survivin is a therapeutic target in Merkel cell carcinoma.P53 mdm2 inhibitors.Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Fragment-based library generation for the discovery of a peptidomimetic p53-Mdm4 inhibitor Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.Protein-protein interactions as drug targets.How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.Chemistry and biology of multicomponent reactions.Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2 MDMX contains an autoinhibitory sequence element.A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.The p53-MDM2/MDMX axis - A chemotype perspective.On the origin of the stereoselective affinity of Nutlin-3 geometrical isomers for the MDM2 protein.Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.Targeting p53-MDM2-MDMX loop for cancer therapy.2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.Multicomponent Reactions, Union of MCRs and Beyond.Reviving the guardian of the genome: Small molecule activators of p53.Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.Synthesis of bioactive and stabilized cyclic peptides by macrocyclization using C(sp3)-H activation.Multicomponent synthesis of diverse 1,4-benzodiazepine scaffolds.One-pot synthesis of 2-amino-indole-3-carboxamide and analogous.Artificial Macrocycles as Potent p53-MDM2 Inhibitors.The N-terminal CCHC zinc finger motif mediates homodimerization of the transcription factor BCL11B.Synthesis of highly substituted imidazole Uracil containing molecules via Ugi-4CR and Passerini-3CR.Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists†.Enantioselective construction of vicinal tetrasubstituted stereocenters by the mannich reaction of silyl ketene imines with isatin-derived ketimines.Enantioselective construction of imidazolines having vicinal tetra-substituted stereocenters by direct Mannich reaction of α-substituted α-isocyanoacetates with ketimines.

P2860

Q26749008-BF97AD2E-F660-4215-BA11-B06128B946DB Q26795719-E08B52DB-83B7-49A8-966B-65ABAF136CB4 Q27674554-B84A0061-B65E-490D-B7EF-DC90F889F153 Q27680560-F73E8182-6741-4E50-99D2-4B6E61BC75F1 Q28388871-23609D90-6424-4CF4-8538-51E548D170B7 Q28481449-338AE5D3-C434-4271-A17E-25E886B2BFB1 Q30574940-79F6620B-8F12-49B7-BE11-B75BE4A8A6C8 Q34079481-E08A4960-F655-48B3-86FC-FFA3FB705971 Q34135430-A690B0B8-E1E5-4FDF-9200-7ADB9F489593 Q34273814-8F989338-5428-47A7-B008-9F30A9BAD08B Q34287830-28A81DA1-81AF-45E6-8191-33D8D6A0BFA8 Q35087851-4FD474F0-80C5-4050-AC80-000AE4DED205 Q35199094-AE7FB0E7-3D69-4741-954D-187555C3A467 Q35596008-0301CF21-9C89-45F9-A4C8-89326FB08662 Q35738960-D66DE99E-0841-4911-B9C0-DA6E5BE2457E Q35824701-328CACCF-5F34-4966-90F3-BB4474370F96 Q35871210-1FD1E532-74DC-4CFF-A11D-05326E56DDFF Q37017587-B6B7E46D-77D2-4D74-8DE3-A4DDFA3FBEF9 Q37026970-6F7B2FE6-93A2-4D3F-9EAF-D12435739FDE Q37276522-F7302B5F-545A-47DB-8182-1B45077FE24B Q37432745-C8852CC4-C8DE-4FA9-8737-EA1D438D31D1 Q37503463-BC067D7A-4FB7-4B4A-B0C9-FA798924E819 Q37525809-9FA3EFF4-E9BF-4A54-B491-F180C2F84953 Q37701743-E8C3B3F6-5A35-4034-90D7-F98328138BF7 Q38247168-C7720970-A0D0-481F-9F1F-E9B84FE3F426 Q38603245-C3B39AE6-B27E-44B2-9129-9CA91BAA2A66 Q38603972-63E165D2-FC88-4961-8FA4-A690A3317FC6 Q39205536-12082516-A951-4CF6-8764-2EA708CA33A9 Q40523781-BF203234-3D4F-40BB-B7EA-213265444B2B Q41528002-089003A2-7262-44B6-B17A-D1EA32494E0E Q41816455-7142342A-B3CC-4990-BD21-D6FFDFF2D0A6 Q42775745-38DA0A6E-E184-45BA-B1B9-6054229EAE1C Q47117285-BA4BDF12-10C5-4772-8C88-BEC5D02101E4 Q47332416-2E24EE93-A5EE-4237-A445-46D0C4AE3C60 Q49849987-A1F56CCF-87E5-45B8-9D1A-872334520717 Q50072047-B2237DAF-4408-4FC0-9989-E332E4163B22 Q50446283-6463DBED-061E-49EF-A6B6-6DE294847D68 Q51339882-3C12887C-66D8-4509-AE6E-C20AD94143A3

P2860

Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

http://www.wikidata.org/entity/Q41861051

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Robust generation of lead comp ...... emistry: p53/Hdm2 antagonists.

@en

type

label

Robust generation of lead comp ...... emistry: p53/Hdm2 antagonists.

@en

prefLabel

Robust generation of lead comp ...... emistry: p53/Hdm2 antagonists.

@en

P1433

Q41861051-494A159A-AF8A-43AD-B033-45252814BCA6

P1476

Q41861051-86945739-575E-49E0-AECC-B5A626642F97

P2093

Q41861051-36B01EDB-DED9-4573-9D43-E47D3681571F

Q41861051-630E8A8A-342F-4F4F-868D-09389F635E73

Q41861051-73D01BFF-9766-49DA-B81A-6BF490BE5C3A

Q41861051-C36FCB44-1713-4B4D-9CAA-1B952EB57DFC

Q41861051-C478AF4B-8A0E-443B-8B06-AF982873C62B

Q41861051-F6F82863-6B5F-4C5F-AA9C-0BB6D4D5CE16

P2860

Q41861051-027A09B1-5EB4-46A4-8453-577995D7419C

Q41861051-030F1D20-1CBA-4A4A-B2C2-99157808105C

Q41861051-1D093F28-C111-42FC-930E-77082A3811ED

Q41861051-26E13904-5CD9-4FD6-9992-DF4EC7E594AF

Q41861051-3775C215-BBB9-4D8F-9D43-12136CD14858

Q41861051-4ED3D39F-2C1E-47AE-988E-A72A335AF6B7

Q41861051-5361B13D-1362-4D6E-B898-A764F5CCE886

Q41861051-5B0185F3-6CD5-43C1-BCC6-402771C22166

Q41861051-5EBD4E45-7352-4C4B-A2A5-DCCFDF19C072

Q41861051-5FF403B7-0814-4049-8536-091B079DE221

P304

Q41861051-41C645E7-C395-46AA-84E3-8FF2E8611D30

P31

Q41861051-72369789-88BB-4E37-AE5F-5EF30BC4B553

P356

Q41861051-5037CE12-9A23-4CCF-9E68-86D76658F946

P407

Q41861051-939BB892-A215-4EB5-B2D0-29CF40F2C4B2

P433

Q41861051-649A8365-B9DC-4992-998D-1E95CD786A08

P478

Q41861051-E668F11F-6F6B-489F-8021-F8FBBE84F394

P50

Q41861051-1EF9137A-2C87-4C29-8709-8CC70A2CE5AA

Q41861051-6E97F610-466F-4545-B10D-A2FB41E963DF

Q41861051-A173B852-13A5-4B7B-B7BA-40CBFA9AE283

Q41861051-A936BDA9-4763-4536-B77A-E4F479B2F9B1

P577

Q41861051-F82CF6AF-CC3D-4B86-9AF5-3769DA0FC2C6

P5875

Q41861051-394EB118-96E2-447B-A01A-2BC662A37E44

P698

Q41861051-F201BB4B-9FB5-4050-9B78-2EB12233BE50

P921

Q41861051-52C87729-34A1-4812-97FF-5287FF814371

P932

Q41861051-7F6284D7-C34B-4595-9176-FEE6E635F6F3

P356

P1433

Angewandte Chemie International Edition

P1476

Robust generation of lead comp ...... hemistry: p53/Hdm2 antagonists

@en

P2093

Barbara Beck

http://www.w3.org/2001/XMLSchema#string

Grzegorz M Popowicz

http://www.w3.org/2001/XMLSchema#string

Siglinde Wolf

http://www.w3.org/2001/XMLSchema#string

Stuti Srivastava

http://www.w3.org/2001/XMLSchema#string

Tad A Holak

http://www.w3.org/2001/XMLSchema#string

Yijun Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs

Reaching for high-hanging fruit in drug discovery at protein-protein interfaces

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays

Anatomy of hot spots in protein interfaces

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

Discovering high-affinity ligands for proteins: SAR by NMR

High-throughput screening of historic collections: observations on file size, biological targets, and file diversity.

Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.

P304

5352-5356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANIE.201001343

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44699315

http://www.w3.org/2001/XMLSchema#string

P698

20575124

http://www.w3.org/2001/XMLSchema#string

P921

computational biology

P932

3772515

http://www.w3.org/2001/XMLSchema#string